» Articles » PMID: 36440420

MDMA for the Treatment of Misophonia, a Proposal

Overview
Specialty Psychiatry
Date 2022 Nov 28
PMID 36440420
Authors
Affiliations
Soon will be listed here.
Abstract

Misophonia is a disorder characterized by negative physical and emotional reactions to certain trigger sounds, such as chewing food. Up to 50% of population samples endorse some symptoms of misophonia, with about 20% having symptoms that impair normal life functioning. Most misophonia patients exhibit intense negative emotions and autonomic arousal (the fight-flight-freeze response) in response to a trigger, similarly to how someone with post-traumatic stress disorder (PTSD) might respond to a trauma trigger. Curiously, misophonia trigger sounds are often most distressing when coming from a specific person, suggesting the disorder may be responsive to interpersonal relationship factors. Treatment of misophonia is currently limited to the use of hearing modifications (e.g., earplugs or headphones) and psychotherapy, but many patients continue to suffer despite these best efforts. Phase 3 clinical trials suggest that MDMA is efficacious at treating the symptoms of autonomic arousal, negative emotions, and interpersonal suffering found in PTSD. As such, we propose that MDMA may represent an ideal treatment for some suffering from severe misophonia. In this perspective article, we review the symptoms of misophonia, and outline how MDMA may be uniquely suited for treating it, perhaps using a protocol analogous to the MAPS Phase 3 studies for PTSD.

Citing Articles

Is misokinesia sensitivity explained by visual attentional orienting? ERP evidence from an emotional oddball task suggests no.

Jaswal S, Handy T PLoS One. 2024; 19(7):e0306464.

PMID: 39074092 PMC: 11285937. DOI: 10.1371/journal.pone.0306464.


Steroids for the Treatment of Misophonia and Misokinesia.

Webb J, Williamson A Case Rep Psychiatry. 2024; 2024:3976837.

PMID: 38269111 PMC: 10805550. DOI: 10.1155/2024/3976837.

References
1.
Hysek C, Schmid Y, Simmler L, Domes G, Heinrichs M, Eisenegger C . MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2013; 9(11):1645-52. PMC: 4221206. DOI: 10.1093/scan/nst161. View

2.
Feduccia A, Mithoefer M . MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84(Pt A):221-228. DOI: 10.1016/j.pnpbp.2018.03.003. View

3.
Kumar S, Tansley-Hancock O, Sedley W, Winston J, Callaghan M, Allen M . The Brain Basis for Misophonia. Curr Biol. 2017; 27(4):527-533. PMC: 5321671. DOI: 10.1016/j.cub.2016.12.048. View

4.
Zuschlag Z, Leventhal K . Rapid and Sustained Resolution of Misophonia-Type Hyperacusis With the Selective Serotonin Reuptake Inhibitor Sertraline. Prim Care Companion CNS Disord. 2021; 23(3). DOI: 10.4088/PCC.20l02731. View

5.
Schwartz P, Leyendecker J, Conlon M . Hyperacusis and misophonia: the lesser-known siblings of tinnitus. Minn Med. 2012; 94(11):42-3. View